CN116440293A - 用于临床的修饰的NK-92 haNK003细胞 - Google Patents

用于临床的修饰的NK-92 haNK003细胞 Download PDF

Info

Publication number
CN116440293A
CN116440293A CN202310355496.3A CN202310355496A CN116440293A CN 116440293 A CN116440293 A CN 116440293A CN 202310355496 A CN202310355496 A CN 202310355496A CN 116440293 A CN116440293 A CN 116440293A
Authority
CN
China
Prior art keywords
cells
cell
hank003
irradiated
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310355496.3A
Other languages
English (en)
Chinese (zh)
Inventor
H·克林格曼
L·博伊赛尔
P·索恩-希翁格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Co
Original Assignee
Immunobiology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Co filed Critical Immunobiology Co
Publication of CN116440293A publication Critical patent/CN116440293A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202310355496.3A 2017-03-08 2018-03-07 用于临床的修饰的NK-92 haNK003细胞 Pending CN116440293A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762468890P 2017-03-08 2017-03-08
US62/468890 2017-03-08
PCT/US2018/021332 WO2018165291A1 (en) 2017-03-08 2018-03-07 MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
CN201880016940.6A CN110418839B (zh) 2017-03-08 2018-03-07 用于临床的修饰的NK-92haNK003细胞

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880016940.6A Division CN110418839B (zh) 2017-03-08 2018-03-07 用于临床的修饰的NK-92haNK003细胞

Publications (1)

Publication Number Publication Date
CN116440293A true CN116440293A (zh) 2023-07-18

Family

ID=63446373

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310355496.3A Pending CN116440293A (zh) 2017-03-08 2018-03-07 用于临床的修饰的NK-92 haNK003细胞
CN201880016940.6A Active CN110418839B (zh) 2017-03-08 2018-03-07 用于临床的修饰的NK-92haNK003细胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880016940.6A Active CN110418839B (zh) 2017-03-08 2018-03-07 用于临床的修饰的NK-92haNK003细胞

Country Status (9)

Country Link
US (5) US10801013B2 (https=)
EP (1) EP3592845A4 (https=)
JP (5) JP7098648B2 (https=)
KR (4) KR102769529B1 (https=)
CN (2) CN116440293A (https=)
AU (2) AU2018231193B2 (https=)
CA (1) CA3053252C (https=)
IL (3) IL268617B2 (https=)
WO (1) WO2018165291A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102769529B1 (ko) 2017-03-08 2025-02-19 이뮤너티바이오, 인크. 임상용 변형된 NK-92 haNK003 세포
WO2020028656A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
KR102665280B1 (ko) * 2018-10-31 2024-05-10 난트퀘스트, 인크. Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거
CN121518401A (zh) * 2018-11-26 2026-02-13 免疫生物公司 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
WO2020205100A1 (en) 2019-03-15 2020-10-08 Nantcell, Inc. Recombinant eril-15 nk cells
EP4003376A4 (en) * 2019-07-26 2023-09-06 Nantkwest, Inc. CD16+NK-92 CELLS PRELOADED WITH ANTIBODIES AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS
AU2020387167B2 (en) * 2019-11-20 2024-10-24 Immunitybio, Inc. Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
CN113646435A (zh) * 2019-12-09 2021-11-12 南克维斯特公司 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
EP4232567A1 (en) * 2020-10-26 2023-08-30 Shoreline Biosciences, Inc. Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用
EP4548096A1 (en) * 2022-06-28 2025-05-07 Cellply S.R.L. Method for the characterization of products for cell therapy
US20250298030A1 (en) * 2024-03-20 2025-09-25 Immunitybio, Inc. Compositions and Methods for NK-92 Cells Expressing Native CD16

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227584A1 (en) * 1995-08-04 1997-02-20 The General Hospital Corporation Transgenic swine and swine cells having human hla genes
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
AU7267398A (en) 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use
CA2289915A1 (en) * 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
DE602005016683D1 (de) 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
IL287051B (en) * 2015-03-27 2022-09-01 Immunitybio Inc nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment
EP4424326A3 (en) 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
KR102769529B1 (ko) 2017-03-08 2025-02-19 이뮤너티바이오, 인크. 임상용 변형된 NK-92 haNK003 세포

Also Published As

Publication number Publication date
IL268617B2 (en) 2025-03-01
CN110418839A (zh) 2019-11-05
US20240010979A1 (en) 2024-01-11
JP2020511131A (ja) 2020-04-16
EP3592845A4 (en) 2020-12-30
AU2021236511A1 (en) 2021-10-28
IL326426A (en) 2026-04-01
US10774310B2 (en) 2020-09-15
JP7806197B2 (ja) 2026-01-26
CA3053252C (en) 2023-02-21
JP7398518B2 (ja) 2023-12-14
CN110418839B (zh) 2023-06-09
EP3592845A1 (en) 2020-01-15
WO2018165291A1 (en) 2018-09-13
US20200347351A1 (en) 2020-11-05
IL268617A (en) 2019-10-31
KR20240010558A (ko) 2024-01-23
IL316209A (en) 2024-12-01
KR20250026391A (ko) 2025-02-25
AU2018231193B2 (en) 2021-07-22
JP2022130596A (ja) 2022-09-06
KR102626748B1 (ko) 2024-01-17
US20180258397A1 (en) 2018-09-13
US12492377B2 (en) 2025-12-09
JP2025038128A (ja) 2025-03-18
AU2018231193A1 (en) 2019-08-08
US11753625B2 (en) 2023-09-12
JP7608580B2 (ja) 2025-01-06
KR20190118204A (ko) 2019-10-17
CA3053252A1 (en) 2018-09-13
KR102769529B1 (ko) 2025-02-19
US10801013B2 (en) 2020-10-13
JP2026063125A (ja) 2026-04-10
US20260078342A1 (en) 2026-03-19
IL316209B1 (en) 2026-03-01
IL268617B1 (en) 2024-11-01
AU2021236511B2 (en) 2021-12-16
JP7098648B2 (ja) 2022-07-11
KR20230074281A (ko) 2023-05-26
JP2024023513A (ja) 2024-02-21
KR102533061B1 (ko) 2023-05-15
US20190300854A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
CN110418839B (zh) 用于临床的修饰的NK-92haNK003细胞
JP7739389B2 (ja) キメラ抗原受容体で修飾されたｎｋ－９２細胞
KR102907902B1 (ko) 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
JP7092404B2 (ja) Ｐｄ－ｌ１キメラ抗原受容体を発現するｎｋ細胞によるｐｄ－ｌ１陽性悪性腫瘍の排除
JP2021516996A (ja) 生物学的に関連する直交サイトカイン／受容体対
CN107523545A (zh) 一种高效稳定表达抗体的杀伤性细胞及其用途
JP2017534280A (ja) 腫瘍を標的にするがｔ細胞を標的にしないサバイビン特異的ｔ細胞受容体
CN113164521A (zh) 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
CN116867519A (zh) 治疗t细胞癌症的方法和材料
US20240366972A1 (en) Chimeric Antigen Receptor-Modified NK-92 Cells
KR20220092543A (ko) 암의 치료를 위한 의약, 조합 의약, 의약 조성물, 면역 응답성 세포, 핵산 전달 비히클 및 제품
CN107523548A (zh) 一种高效稳定表达抗体的t细胞及其用途
WO2025106626A1 (en) Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
CN113549157A (zh) 双靶向嵌合抗原受体及其应用
CN115348868A (zh) 表达bcma特异性嵌合抗原受体的基因工程化t细胞及其在癌症疗法中的用途
HK40095411A (zh) 用於临床的修饰的nk-92 hank003细胞
EP4326854A1 (en) Chimeric antigen receptor (car)-t cells
HK40011833A (en) Modified nk-92 hank003 cells for the clinic
US20240207313A1 (en) Chimeric antigen receptor (car)-t cells
HK40119596A (zh) 嵌合抗原受体修饰的nk-92细胞
HK40038924B (en) Fc-epsilon car

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095411

Country of ref document: HK